Literature DB >> 30309292

The ART of Antiretroviral Therapy in Critically Ill Patients With HIV.

Tyler Finocchio1, William Coolidge1, Thomas Johnson1.   

Abstract

The management of patients with human immunodeficiency virus (HIV) can be a complicated specialty within itself, made even more complex when there are so many unanswered questions regarding the care of critically ill patients with HIV. The lack of consensus on the use of antiretroviral medications in the critically ill patient population has contributed to an ongoing clinical debate among intensivists. This review focuses on the pharmacological complications of antiretroviral therapy (ART) in the intensive care setting, specifically the initiation of ART in patients newly diagnosed with HIV, immune reconstitution inflammatory syndrome (IRIS), continuation of ART in those who were on a complete regimen prior to intensive care unit admission, barriers of drug delivery alternatives, and drug-drug interactions.

Entities:  

Keywords:  acquired immune deficiency syndrome; antiretroviral; drug delivery; human immunodeficiency virus; immune reconstitution inflammatory syndrome; intensive care unit

Year:  2018        PMID: 30309292     DOI: 10.1177/0885066618803871

Source DB:  PubMed          Journal:  J Intensive Care Med        ISSN: 0885-0666            Impact factor:   3.510


  2 in total

1.  Erratic enteric absorption of dolutegravir in a critically ill patient.

Authors:  M de Antonio-Cuscó; F J Parrilla; H Knobel Freud; D Echeverría-Esnal; A Castellví Font; A Vázquez; J R Masclans; O Ferrández; S Grau
Journal:  Rev Esp Quimioter       Date:  2022-05-30       Impact factor: 2.515

2.  Identification of HIV-1-specific cascaded microRNA-mRNA regulatory relationships by parallel mRNA and microRNA expression profiling with AIDS patients after antiviral treatment.

Authors:  Fangyuan Shen; Yefang Liu; Lanchun Wang; Xiaoqiang Chai; Jian Yang; Quansheng Feng; Xiao Li
Journal:  Medicine (Baltimore)       Date:  2021-11-05       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.